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CASE REPORT
Proof of principle for bevacizumab 
activity in desmoid-type fibromatosis
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Abstract 
Background: Desmoid-type fibromatosis (DF) is a rare disease, which often occurs in young adults. Medical treat-
ment is an important option in the treatment algorithm of DF. Different chemotherapeutic regimens showed clinical 
activity in DF, but overall treatment tolerability remains poor for this patient cohort. Novel approaches investigated 
tyrosine kinase inhibitors in DF, but tolerability remained an issue.
Case presentation: We treated a patient with progressive DF after failure of chemotherapy for 1 year with singe 
agent bevacizumab. He achieved a symptomatic and radiologic response while attainning excellent tolerability.
Conclusions: This is the first report on single agent bevacizumab in DF, which showed both, good tolerability and 
efficacy in our patient, thereby warranting future trials in DF.
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Background
Desmoid-type fibromatosis (DF) is a rare disease with 
an annual incidence of 3–4 cases per 1 million inhabit-
ants, which is characterized by a variable and unpredict-
able clinical course. DF may occur at varying ages, but 
the majority of patients are diagnosed as young adults 
with a peak incidence at approximately 30 years [1]. Only 
a minority of 5–10 % of DF cases is associated with the 
familial adenomatous polyposis (FAP), an inherent dis-
ease with APC germ line mutation [2, 3].
Per definition, DF is a benign but clonal fibroblas-
tic proliferation. It lacks the ability to form metastases, 
but its high local recurrence rate debilitates patients 
and affects their quality of life [4]. Therefore the choice 
of therapy should be made after interdisciplinary coun-
seling, tailoring the treatment to the patients need. 
Because the natural course of the disease varies, differ-
ent groups recommend active surveillance as the pri-
mary approach to these patients [3, 5]. Upon progression, 
treatment may consist of medical treatment, surgery or 
radiotherapy.
Discussing the merits of therapy also includes its major 
limitation, which in the case of surgery is the loss of func-
tion or its mutilating character. While medical treatment 
is associated with chronic exposure and toxicity may 
limit its prolonged use, radiotherapy offers some advan-
tage with a single exposure, but the risk of secondary 
neoplasias is of specific interest in this non-malignant 
disease of mainly young adults [3].
Medical treatment is an option in progressive DF, 
which is used in patients who would require mutilating 
surgery or in the recurrent setting [4]. The agents used 
may vary from anti-inflammatory agents to chemother-
apeutics. Methotrexate (MTX)/vinblastine (VBL) is a 
standard treatment approach in DF, which is intended to 
be given for a treatment duration of 1 year [3]. However, 
despite the good tolerability in metastatic cancers, MTX/
VBL causes significant toxicity in DF, which hampers the 
continuation of treatment and requires treatment adjust-
ments frequently [3]. In a recent pediatric phase II study 
only 50 % of patients finished the pre-specified treatment 
duration, and 64 % grade 3/4 toxicity was reported [6].
As an alternative approach, a recent study reported on 
the efficacy of sorafenib in DF. An objective response rate 
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(ORR) of 25 % was achieved, indicating explicit efficacy in 
DF [7]. The median duration of sorafenib treatment was 
5  months. The median daily dose of sorafenib was only 
200  mg, which is ¼ of the standard dose in metastatic 
cancers (800  mg/day), indicating that distinct patient 
populations may exert distinct tolerability of treatment. 




We report on a case of a 16-year old male patient who 
was diagnosed with DF of the right upper thorax in 2011 
(Fig. 1). The primary approach consisted of partial tumor 
resection for functional preservation. Systemic therapy 
with MTX/VBL was started after completion of surgery 
in order to maintain tumor control. However, MTX-asso-
ciated nausea and fatigue led to discontinuation of MTX 
after 6  months of treatment. Instead, sulfonylurea had 
been added to VBL, but again, nausea limited the appli-
cability of this combination and treatment was provided 
as single agent sulfonylurea.
Two years after the initial resection, a symptomatic 
tumor recurrence was detected while receiving medical 
treatment. Local recurrence involved the right brachial 
plexus, which was incompletely resected for the purpose 
of function preservation.
Systemic therapy was reconvened with MTX and 
vinorelbine, which achieved symptomatic improve-
ment of pain with disease stabilization as best response 
on MRI. However, the treatment was not sustainable 
because of grade 1 nausea and fatigue and led to treat-
ment discontinuation after 4 months.
Within 4  months, the patient complained of recur-
rence of grade 1 tumor pain and the MRI showed gradual 
tumor growth. At this time, radiotherapy was not consid-
ered appropriate given the young age and the proximity 
to the plexus nerves, instead medical treatment was dis-
cussed with the patient. Re-challenge with chemother-
apy was not preferred by the patient, and an individual 
approach to medical treatment was sought. Based on the 
hyperperfusion of the patient’s tumor and the promising 
results of sorafenib in DF, we implied future treatment 
with bevacizumab 15  mg/kg q3wks., given the excellent 
tolerability profile of this agent.
During the course of treatment, tumor pain disappeared 
and the patient experienced functional improvement. 
Initial radiological response was detected after 1 month, 
with a tumorshrinkage of 16 %. Treatment was continued 
for a total duration of 12 months with a further decrease 
in tumor diameter of 38  % (Fig.  2). Further follow-up is 
performed by 3 months intervals by MRI and clinical vis-
its. The first post-therapy scan confirmed tumor response 
in our patient, indicating sustained clinical activity.
Discussion
Desmoid-type fibromatosis is a rare disease, which often 
occurs in young adults. Its lack of metastatic potential 
requires a distinct approach to treatment. Patients are 
not limited in their survival expectation, which renders 
long-term morbidity as a key factor for the process of 
shared decision-making. Medical treatment is an option 
for patients facing mutilating surgery. MTX/VBL with 
weekly applications is considered a well-tolerated agent 
in cancer patients. However, the treatment may be differ-
entially anticipated in patients with DF, which is reflected 
Fig. 1 MRI of the right shoulder showing the tumor extent at the time of initial diagnosis in proton density (PD)-weighted (a) and T1-weighted 
contrast-enhanced (b) sequences. An inhomogeneously enhancing, partially fibrotic tumor (white arrows) originating from the right thoracic wall is 
clearly visible consistent with a desmoid-type fibromatosis
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by the high rate of treatment discontinuation in current 
patient series [3].
VEGFR inhibitors, such as sorafenib, exert an interest-
ing activity in DF. However, these agents are associated 
with a high rate of grade 3/4 adverse events in >70 % of 
patients [8], and therefore represent an alternative for 
symptomatic patients who experience a DF-associated 
decrease in their daily activities.
Medical treatment is often chronic and requires long-
term exposure, which renders VEGRF inhibitors not an 
ideal match for most patients. Based on the mechanism 
of action and the proof of principle by this class of agents, 
bevacizumab seems to be an attractive alternative with 
only a fraction of grade 3/4 adverse events (44  %) [9]. 
However, safety of bevacizumab is not well studied in 
children and adolescent patients and therefore should be 
used with caution in this population.
Our case report supports this notion with tumor 
shrinkage of DF and symptomatic improvement. The 
excellent tolerability of bevacizumab fits the needs of DF 
patients in many ways. The young age of most patients 
puts them into a scenario, where function and well-being 
is essential in their daily life. Our patient graduated suc-
cessfully from secondary school while receiving bevaci-
zumab treatment, indicating the excellent tolerability of 
this treatment.
Further studies with bevacizumab are warranted and 
should be pursuit in DF patients.
Fig. 2 T2-weighted MRI of the right shoulder after second tumor resection and prior to bevacizumab treatment (a), as well as 6 weeks (b), 
4 months (c) and 14 months (d) after treatment initiation, showing a continuous tumor shrinkage over time (white arrows)
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Conclusion
Medical treatment of DF remains divers. While the 
majority of patients receive chemotherapy for tumor con-
trol, hormone ablation is used in selected cases, such as 
abdominal wall DF in young women. Novel approaches 
employ tyrosine kinase inhibitors, but given the vulner-
ability of this patient population, novel approaches are 
needed. In our patient bevacizumab achieved excellent 
tumor control with only a fraction of adverse events com-
pared to conventional chemotherapy. Given the balance 
between efficacy and tolerability, bevacizumab may rep-
resent a suitable well-tolerated agent in DF and should be 
further explored in clinical trials.
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